Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indivior PLC

www.indivior.com

Latest From Indivior PLC

Dual Injection Approvals? A Comparison Of Indivior, Braeburn Buprenorphine Products

US FDA might approve Indivior and Braeburn's injectable buprenorphine products simultaneously; here's a side-by-side look at the advantages and disadvantages of each.

Advisory Committees Drug Review

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Indivior, Braeburn, And Two Very Well-Timed Anti-Addiction Applications

US FDA advisory committee had dosing and dispensing concerns about both buprenorphine injectable products, but each ended up with a strong vote in favor, clearly benefiting from public health attention to opioid addiction and the call for broader access to treatment.

Advisory Committees Drug Review

Braeburn's Buprenorphine Clears Advisory Committee, But US FDA Likely To Limit Dosage

Seventeen of the panelists voted that the clinical data support approval for some of Braeburns proposed doses, but no one supported the highest proposed monthly dose.

Advisory Committees Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Reckitt Benckiser Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Indivior PLC
  • Senior Management
  • Shaun Thaxter, CEO
    Cary Claiborne, CFO
    Tim Baxter, MD, CMO
    Tony Goodman, Chief Bus. Dev. Officer
    Christian Heidbreder, PhD, CSO
    Richard Simkin, Chief Commercial Officer
  • Contact Info
  • Indivior PLC
    Phone: (0)1753 217800
    215 Bath Rd.
    Slough, SL1 4AA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register